• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Hereditary hemorrhagic telangiectasia
Rev Mal Respir. 2023 Apr 14:S0761-8425(23)00136-5. doi: 10.1016/j.rmr.2023.02.007. Online ahead of print.ABSTRACTHereditary hemorrhagic telangiectasia, also known as Rendu-Osler - Weber disease, is a rare, autosomal dominant vascular disease, with prevalence of 1/5,000. The condition is characterized by muco-cutaneous telangiectasias, which are responsible for a hemorrhagic syndrome of variable severity, as well as arteriovenous malformations (AVMs) appearing in the lungs, the liver, and the nervous system. They can be the source of shunts, which may be associated with high morbidity (neurological ischemic stroke, brain ab...
Source: Revue des Maladies Respiratoires - April 16, 2023 Category: Respiratory Medicine Authors: A Parrot M Barral X Amiot C Bachmeyer I Wagner M Eyries S Alamowitch S Ederhy R Epaud S Dupuis-Girod J Cadranel Source Type: research

Vascular complications in glioma patients.
Abstract Vascular complications in patients with glioma most commonly include venous and arterial thromboembolism; however, treatment-induced vasculopathies are also problematic, especially in long-term survivors. The interactions between treatment such as radiation and chemotherapy, the coagulation cascade, endothelium, and regulators of angiogenesis are complex, drive glioma growth and invasion, and create common management problems in the clinic. We review the incidence of thrombotic complications in glioma, the biology of the coagulome as related to glioma progression, prevention and treatment of thrombosis, t...
Source: Clinical Genitourinary Cancer - December 16, 2016 Category: Cancer & Oncology Authors: Le Rhun E, Perry JR Tags: Handb Clin Neurol Source Type: research

Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia : A  case report.
CONCLUSION: Intermittent low-dose therapy with bevacizumab represents an effective and cost-efficient treatment option for transfusion-dependent patients with hereditary hemorrhagic telangiectasia. PMID: 27878613 [PubMed - as supplied by publisher]
Source: Wiener Klinische Wochenschrift - November 22, 2016 Category: Journals (General) Authors: Huemer F, Dejaco M, Grabmer C, Melchardt T, Neureiter D, Mayer G, Egle A, Greil R, Weiss L Tags: Wien Klin Wochenschr Source Type: research

Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy
Conclusion The safety profile was consistent with that expected from radiotherapy/temozolomide plus bevacizumab. The increased AE incidence with bevacizumab did not impact patients' ability to receive standard-of-care treatment or to undergo further surgery.
Source: Neuro-Oncology - June 6, 2016 Category: Cancer & Oncology Authors: Saran, F., Chinot, O. L., Henriksson, R., Mason, W., Wick, W., Cloughesy, T., Dhar, S., Pozzi, E., Garcia, J., Nishikawa, R. Tags: Clinical Investigations Source Type: research

Vascular complications in glioma patients.
Abstract Vascular complications in patients with glioma most commonly include venous and arterial thromboembolism; however, treatment-induced vasculopathies are also problematic, especially in long-term survivors. The interactions between treatment such as radiation and chemotherapy, the coagulation cascade, endothelium, and regulators of angiogenesis are complex, drive glioma growth and invasion, and create common management problems in the clinic. We review the incidence of thrombotic complications in glioma, the biology of the coagulome as related to glioma progression, prevention and treatment of thrombosis, t...
Source: Clinical Genitourinary Cancer - March 9, 2016 Category: Cancer & Oncology Authors: Le Rhun E, Perry JR Tags: Handb Clin Neurol Source Type: research

Chapter 15 Vascular complications in glioma patients
Publication date: 2016 Source:Handbook of Clinical Neurology, Volume 134 Author(s): Emilie Le Rhun, James R. Perry Vascular complications in patients with glioma most commonly include venous and arterial thromboembolism; however, treatment-induced vasculopathies are also problematic, especially in long-term survivors. The interactions between treatment such as radiation and chemotherapy, the coagulation cascade, endothelium, and regulators of angiogenesis are complex, drive glioma growth and invasion, and create common management problems in the clinic. We review the incidence of thrombotic complications in glioma, the...
Source: Handbook of Clinical Neurology - March 4, 2016 Category: Neurology Source Type: research

Summary: International Kidney Cancer Symposium
Conclusions:  Ideal ischemia time is 20-25 minutes or less improves short and long term renal function.  >25 minutes carried 5 year risk of new onset stage 4 CKD No differences on GFR for cold vs. warm ischemia times Preoperative GFR and the percent of kidney preserved was a better predictor of post op GFR.  No ischemia preserves renal function better than warm. Longer cold ischemia times were equivalent to shorter warm ischemia times. Quality and quantity of the remaining kidney is associated with ultimate renal function. Robotics in RCC Surgery Gennady Bratslavsky, MD The...
Source: Kidney Cancer Association - December 15, 2011 Category: Urology & Nephrology Source Type: news